Aventis abandons cariporide
Executive Summary
Aventis will not seek regulatory approval for cariporide, company says May 16. Phase III trial for cardiovascular drug candidate was halted in July 2002 by data safety monitoring board (1"The Pink Sheet" Feb. 24, p. 24)...